[1] Farghaly SA.Current diagnosis and management of ovarian cysts[J].Clin Exp Obstet Gynecol,2014,41(6):609-612.
[2] Ovarian Cysts in Postmenopausal Women(Green-top Guideline No.34)[EB/OL].(2016-07-19)[2021-08-10].https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg34/.
[3] 李会阳,王颖梅,薛凤霞.绝经后卵巢囊肿的处理[J].中国实用妇科与产科杂志,2018,34(4):458-461.
[4] Daly MB,Pilarski R,Yurgelun MB,et al.NCCN Guidelines Insights:Genetic/Familial High-Risk Assessment:Breast,Ovarian,and Pancreatic,Version 1.2020[J].J Natl Compr Canc Netw,2020,18(4):380-391.
[5] 中国抗癌协会肿瘤内分泌专业委员会,中国优生科学协会女性生殖道疾病诊治分会,中国优生科学协会肿瘤生殖学分会.遗传性妇科肿瘤高风险人群管理专家共识(2020)[J].中国实用妇科与产科杂志,2020,36(9):825-834.
[6] Timmerman D,Planchamp F,Bourne T,et al.ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors[J].Int J Gynecol Cancer,2021,31(7):961-982.
[7] 张燕,毛林.绝经后卵巢包块诊断策略[J].中国实用妇科与产科杂志,2020,36(12):1148-1152.
[8] Myers ER,Bastian LA,Havrilesky LJ,et al.Management of adnexal mass[J].Evid Rep Technol Assess (Full Rep),2006,(130):1-145.
[9] Urban N,Thorpe J,Karlan BY,et al.Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer[J].Cancer Epidemiol Biomarkers Prev,2012,21(11):2087-2094.
[10] Moore RG,McMeekin DS,Brown AK,et al.A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass[J].Gynecol Oncol,2009,112(1):40-46.
[11] Azeez HAA,Labib HA,Sharaf SM,et al.HE4 and mesothelin:novel biomarkers of ovarian carcinoma in patients with pelvic masses[J].Asian Pac J Cancer Prev,2010,11(1):111-116.
[12] Nolen B,Velikokhatnaya L,Marrangoni A,et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass[J].Gynecol Oncol,2010,117(3):440-445.
[13] Solnik MJ,Alexander C.Ovarian incidentaloma[J].Best Pract Res Clin Endocrinol Metab,2012,26(1):105-116.
[14] Avesani G,Arshad M,Lu H,et al.Radiological assessment of Peritoneal Cancer Index on preoperative CT in ovarian cancer is related to surgical outcome and survival[J].Radiol Med,2020,125(8):770-776.
[15] Nasser S,Lazaridis A,Evangelou M,et al. Correlation of pre-operative CT findings with surgical &;histological tumor dissemination patterns at cytoreduction for primary advanced and relapsed epithelial ovarian cancer:A retrospective evaluation[J].Gynecol Oncol,2016,143(2):264-269.
[16] Anthoulakis C,Nikoloudis N. Pelvic MRI as the "gold standard" in the subsequent evaluation of ultrasound-indeterminate adnexal lesions:a systematic review[J].Gynecol Oncol,2014,132(3):661-668.
[17] Dohan A,Hoeffel C,Soyer P,et al.Evaluation of the peritoneal carcinomatosis index with CT and MRI[J].Br J Surg,2017,104(9):1244-1249.
[18] Low RN,Barone RM,Lucero J.Comparison of MRI and CT for predicting the Peritoneal Cancer Index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures[J].Ann Surg Oncol,2015,22(5):1708-1715.
[19] Torkzad MR,Casta N,Bergman A,et al.Comparison between MRI and CT in prediction of peritoneal carcinomatosis index (PCI) in patients undergoing cytoreductive surgery in relation to the experience of the radiologist[J].J Surg Oncol,2015,111(6):746-751.
[20] Gadelhak B,Tawfik AM,Saleh GA,et al.Extended abdominopelvic MRI versus CT at the time of adnexal mass characterization for assessing radiologic peritoneal cancer index (PCI) prior to cytoreductive surgery[J].Abdom Radiol (NY),2019,44(6):2254-2261.
[21] Fenchel S,Grab D,Nuessle K,et al.Asymptomatic adnexal masses:correlation of FDG PET and histopathologic findings[J].Radiology,2002,223(3):780-788.
[22] Wahl RL,Javadi MS,Eslamy H,et al.The Roles of Fluorodeoxyglucose-PET/Computed Tomography in Ovarian Cancer:Diagnosis,Assessing Response,and Detecting Recurrence[J].PET Clin,2010,5(4):447-461.
[23] Moore RG,Brown AK,Miller MC,et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J].Gynecol Oncol,2008,108(2):402-408.
[24] Westwood M,Ramaekers B,Lang S,et al.Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care:a systematic review and cost-effectiveness analysis[J].Health Technol Assess,2018,22(44):1-264.
[25] Chacón E,Dasí J,Caballero C,et al.Risk of Ovarian Malignancy Algorithm versus Risk Malignancy Index-I for Preoperative Assessment of Adnexal Masses:A Systematic Review and Meta-Analysis[J].Gynecol Obstet Invest,2019,84(6):591-598.
[26] Timmerman D.The use of mathematical models to evaluate pelvic masses:can they beat an expert operator?[J].Best Pract Res Clin Obstet Gynaecol,2004,18(1):91-104.
[27] Calster BV,Valentin L,Froyman W,et al.Validation of models to diagnose ovarian cancer in patients managed surgically or conservatively:multicentre cohort study[J].BMJ,2020,370:m2614.
[28] Calster BV,Hoorde KV,Valentin L,et al.Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign,borderline,early and advanced stage invasive,and secondary metastatic tumours:prospective multicentre diagnostic study[J].BMJ,2014,349:g5920.
[29] Behnamfar F,Adibi A,Khadra H,et al.Diagnostic accuracy of gynecology imaging reporting and data system in evaluation of adnexal lesions[J].J Res Med Sci,2019,24:57.
[30] Migda M,Bartosz M,Migda MS,et al.Diagnostic value of the gynecology imaging reporting and data system (GI-RADS) with the ovarian malignancy marker CA-125 in preoperative adnexal tumor assessment[J].J Ovarian Res,2018,11(1):92.
[31] Basha MAA,Refaat R,Ibrahim SA,et al.Gynecology Imaging Reporting and Data System (GI-RADS):diagnostic performance and inter-reviewer agreement[J].Eur Radiol,2019,29(11):5981-5990.
[32] Andreotti RF,Timmerman D,Benacerraf BR,et al. Ovarian-Adnexal Reporting Lexicon for Ultrasound:A White Paper of the ACR Ovarian-Adnexal Reporting and Data System Committee[J].J Am Coll Radiol,2018,15(10):1415-1429.
[33] Andreotti RF,Timmerman D,Strachowski LM,et al.O-RADS US Risk Stratification and Management System:A Consensus Guideline from the ACR Ovarian-Adnexal Reporting and Data System Committee[J].Radiology,2020,294(1):168-185.
[34] Basha MAA,Metwally MI,Gamil SA,et al.Comparison of O-RADS,GI-RADS,and IOTA simple rules regarding malignancy rate,validity,and reliability for diagnosis of adnexal masses[J].Eur Radiol,2021,31(2):674-684.
[35] Greenlee RT,Kessel B,Williams CR,et al.Prevalence,incidence,and natural history of simple ovarian cysts among women aged >;55 years old in a large cancer screening trial[J].Am J Obstet Gynecol,2010,202(4):373.
[36] Baheti AD,Lewis CE,Hippe DS,et al.Adnexal lesions detected on CT in postmenopausal females with non-ovarian malignancy:do simple cysts need follow-up?[J].Abdom Radiol (NY),2019,44(2):661-668.
[37] van de Vrie R,Rutten MJ,Asseler JD,et al.Laparoscopy for diagnosing resectability of disease in women with advanced ovarian cancer[J].Cochrane Database Syst Rev,2019,3(3):CD009786.
[38] National Collaborating Centre for Cancer(UK). Ovarian Cancer:The Recognition and Initial Management of Ovarian Cancer[M].Cardiff(UK):National Collaborating Centre for Cancer(UK),2011:PMID:22479719.
[39] Kehila M,Kebaili S,Hidar S,et al.Ovarian tumors in postmenopausal women:report of 100 cases and review of the literature[J].Pan Afr Med J,2014,19:235.
[40] 王稳,崔秀娟,张师前.绝经后卵巢良性肿瘤诊治的相关问题[J].中国妇产科临床杂志,2019,20(6):564-566.